Spexis is a clinical-stage biopharma focused on macrocycles for rare diseases & oncology.
ColiFin® is US Ph 3-ready for testing in chronic cystic fibrosis lung infections; developed with an equity investment by the Cystic Fibrosis Foundation. Inhaled murepavadin is in Ph 1 for chronic CF lung infections and has strong potential in non-CF bronchiectasis (nCFBE) and COPD.
Balixafortide has been in 8 clinical trials totaling >500 subjects in oncology and non-oncology and is being assessed for further clinical trials.
Spexis has a novel, proprietary macrocycle platform with extensive peptidic/non-peptidic libraries, databases & IP & has generated various clinical & preclinical compounds. The platform is expected to fuel the pipeline and create partnering opportunities.
Spexis at a glance:
|Field of Activity||Discovering and developing treatments for rare diseases and oncology, with an initial focus on chronic respiratory diseases including cystic fibrosis|
|Ownership Structure and Financing||Publicly listed on Swiss SIX stock exchange; symbol – SPEX|
|Partners||Funding for certain programs from CF Foundation, Innovative Medicines Initiative & CARB-X.
Fosun Pharma: China rights Balixafortide
|Technology||Macrocycle platform: 2 distinct, well characterized libraries plus deep data: PEMfinder®-peptidomimetic macrocycles and MACROfinder®-small, non-peptidic molecules|
|Unique Selling Point||• Ph 3-ready + Ph 1 assets for CF infections
• Balixafortide-oncology, hematologic and rare disease indications
• Macrocycle platform for new programs and partnering
|Date of Incorporation/
Number of Employees
|Launch of Spexis December 2021 (merger close) /27|
|Telephone||+41 61 567 16 00|